Cardiol Therapeutics Inc. Class A Common Shares (CRDL)

Price$1.51

Favorite Metrics

Price vs S&P 500 (26W)32.35%

Price vs S&P 500 (4W)50.20%

Market Capitalization$156.50M

All Metrics

Book Value / Share (Quarterly)$0.13

P/TBV (Annual)6.12x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.17

Price vs S&P 500 (YTD)53.89%

EPS (TTM)$-0.29

10-Day Avg Trading Volume0.13M

EPS Excl Extra (TTM)$-0.29

EPS (Annual)$-0.38

ROI (Annual)-147.38%

Net Profit Margin (5Y Avg)-143204.20%

Cash / Share (Quarterly)$0.16

ROA (Last FY)-115.11%

EBITD / Share (TTM)$-0.29

ROE (5Y Avg)-100.84%

Cash Flow / Share (Annual)$-0.17

P/B Ratio11.95x

P/B Ratio (Quarterly)7.33x

Net Income / Employee (Annual)$-1

Net Interest Coverage (TTM)-0.89x

ROA (TTM)-165.05%

EPS Incl Extra (Annual)$-0.38

Current Ratio (Annual)4.16x

Quick Ratio (Quarterly)3.83x

3-Month Avg Trading Volume0.11M

52-Week Price Return47.14%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.22

P/S Ratio (Annual)2670.95x

Asset Turnover (Annual)0.00x

52-Week High$2.17

Operating Margin (5Y Avg)-156141.00%

EPS Excl Extra (Annual)$-0.38

CapEx CAGR (5Y)-9.35%

Tangible BV CAGR (5Y)11.86%

26-Week Price Return41.10%

Quick Ratio (Annual)3.83x

13-Week Price Return53.73%

Total Debt / Equity (Annual)0.01x

Current Ratio (Quarterly)4.16x

Enterprise Value$140.907

Book Value / Share Growth (5Y)-15.08%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-39550.00%

Cash / Share (Annual)$0.16

3-Month Return Std Dev66.45%

Net Income / Employee (TTM)$-1

ROE (Last FY)-148.32%

Net Interest Coverage (Annual)-11.32x

EPS Basic Excl Extra (Annual)$-0.38

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.01x

EPS Incl Extra (TTM)$-0.29

Receivables Turnover (Annual)0.00x

ROI (TTM)-235.72%

Pretax Margin (5Y Avg)-143204.20%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.22

Price vs S&P 500 (52W)12.05%

Year-to-Date Return57.25%

5-Day Price Return8.99%

EPS Normalized (Annual)$-0.38

ROA (5Y Avg)-81.50%

Net Profit Margin (Annual)-39550.00%

Month-to-Date Return8.99%

Cash Flow / Share (TTM)$-0.32

EBITD / Share (Annual)$-0.41

Operating Margin (Annual)-48325.00%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-100.13%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.29

P/TBV (Quarterly)6.12x

P/B Ratio (Annual)7.33x

Book Value / Share (Annual)$0.13

Price vs S&P 500 (13W)50.87%

Beta1.88x

Revenue / Share (TTM)$0.00

ROE (TTM)-238.02%

52-Week Low$1.23

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

4.13

About

Cardiol Therapeutics is a late-stage biopharmaceutical company developing anti-inflammatory and anti-fibrotic therapies for heart disease. Its lead candidate, CardiolRx, is advancing through Phase III trials for pericarditis treatment and has completed Phase II studies in myocarditis and heart failure. The company is also developing CRD-38, a subcutaneous formulation targeting inflammatory heart conditions.